ZBIOZenas BioPharma, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$34M

Operating Income

-$41M

Net Income

-$39M

EPS (Diluted)

$-0.92

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$403M

Total Liabilities

$44M

Stockholders' Equity

$359M

Cash & Equivalents

$360M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$50M	-100.0%
Gross Profit	-$34M	$50M	-167.1%
Operating Income	-$41M	$36M	-215.0%
Net Income	-$39M	$36M	-208.4%

ZBIO Q3 2024 Earnings — Zenas BioPharma, Inc. Revenue & Financial Results | Market Cap Arena